Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era

Michael J Buege, PharmD, Phuong H Dao, PharmD, Esther Drill, DrPH, Andréa C LeVoir, PharmD, Terry Pak, PharmD, Tim J Peterson, PharmD, David J. Straus, MD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-134607

Published: 2020

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Benjamin Diamond, MD, Neha Korde, MD, Alexander M. Lesokhin, MD, Eric L Smith, MDPhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X. Lu, MD PhD, Carlyn Tan, MD, Donna Massey, MSN, RN, Meghan Salcedo, BSN, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Kathryn Ciardiello, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata D Yellapantula, Francesco Maura, MD, Tim J Peterson, PharmD, Andriy Derkach, PhD, Sean Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan L. Shah, MDMS, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-140152

Published: 2020

Journal Articles

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Katrina M Piedra, PharmD, Hani Hassoun, MD, Larry W. Buie, PharmD, BCOP, FASHP, Sean M. Devlin, PhD, Jessica Flynn, BS, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sydney X Lu, MD PhD, Sham Mailankody, MBBS, Urvi A Shah, MD, Eric L Smith, MD PhD, Ola Landgren, MD PhD, Neha Korde, MD, Tim J Peterson, PharmD

Blood (2019) 134 (Supplement_1): 1835.

https://doi.org/10.1182/blood-2019-124403

Published: 2019

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Donna Mastey, RN, Alexander M. Lesokhin, MD, Eric L Smith, MD PhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X Lu, MD PhD, Meghan Salcedo, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Ciardiello, BS, Elizabeth Tavitian, BS, Tala Shekarkhand, BS, Even Rustad, MD, Venkata Yellapantula, PhD, Francesco Maura, MD, Tim J Peterson, PharmD, Sean M. Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, PhD, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio Giralt, MD, Neha Korde, MD

Blood (2019) 134 (Supplement_1): 3127.

https://doi.org/10.1182/blood-2019-125842

Published: 2019

Journal Articles

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Tim J Peterson, PharmD, Neha Korde, MD, Hani Hassoun, MD, Sham Mailankody, MBBS, Alexander M. Lesokhin, MD, Malin Hultcrantz, MD PhD, Urvi A Shah, MD, Eric L Smith, MD PhD, Sydney X Lu, MD PhD, Heather J Landau, MD, Gunjan L. Shah, MD, Michael Scordo, MD, Oscar B Lahoud, MD, Sergio A Giralt, MD, Ola Landgren, MD PhD

Blood (2019) 134 (Supplement_1): 5554.

https://doi.org/10.1182/blood-2019-124376

Published: 2019

Journal Articles

Effects of Obesity on the Efficacy and Toxicity of Induction Chemotherapy in Adult Acute Lymphoblastic Leukemia (ALL)

Tim J Peterson, PharmD, Andrew Lin, PharmD, BCOP, Patrick Hilden, MS, Sean Devlin, PhD, Nelly G. Adel, PharmD, BCOP, BCPS, Jae H Park, MD

Blood (2015) 126 (23): 1290.

https://doi.org/10.1182/blood.V126.23.1290.1290

Published: 2015

NARROW

IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Effects of Obesity on the Efficacy and Toxicity of Induction Chemotherapy in Adult Acute Lymphoblastic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Effects of Obesity on the Efficacy and Toxicity of Induction Chemotherapy in Adult Acute Lymphoblastic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only